{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:51:25Z","timestamp":1792086685529,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Histol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10735-026-11013-9","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:06Z","timestamp":1792068846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF\u20111\u03b1 expression, and histopathological injury profile"],"prefix":"10.1007","volume":"57","author":[{"given":"Ulya","family":"Keskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslem","family":"Alt\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikriye Yasemin","family":"\u00d6zatik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Ko\u00e7ak","family":"Sezgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe \u00c7ak\u0131r","family":"G\u00fcndo\u011fdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neziha Senem","family":"Ar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4438-5689","authenticated-orcid":false,"given":"Melkan Ka\u011fan","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"11013_CR14","doi-asserted-by":"publisher","first-page":"1551088","DOI":"10.3389\/fcdhc.2025.1551088","volume":"6","author":"GI Adebayo-Gege","year":"2025","unstructured":"Adebayo-Gege GI, Adegbola PI, Adedayo LD, Oyefabi AM, Oyeyemi IT, Olubukola O et al (2025) Prevalence of nephropathy among patients with diabetes mellitus in Africa: a systematic review and meta-analysis. Front Clin Diabetes Healthc 6:1551088. https:\/\/doi.org\/10.3389\/fcdhc.2025.1551088","journal-title":"Front Clin Diabetes Healthc"},{"issue":"1","key":"11013_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT et al (2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13(1):15\u201328. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"11013_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00125-021-05380-z","volume":"64","author":"SB Catrina","year":"2021","unstructured":"Catrina SB, Zheng X (2021) Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia 64(4):709\u2013716. https:\/\/doi.org\/10.1007\/s00125-021-05380-z","journal-title":"Diabetologia"},{"key":"11013_CR27","first-page":"212","volume-title":"Ordinal Methods for Behavioral Data Analysis","author":"N Cliff","year":"1996","unstructured":"Cliff N (1996) Ordinal Methods for Behavioral Data Analysis. Lawrence Erlbaum Associates, Mahwah, NJ, p 212"},{"issue":"21","key":"11013_CR9","doi-asserted-by":"publisher","first-page":"e194749","DOI":"10.1172\/JCI194749","volume":"135","author":"ME Cooper","year":"2025","unstructured":"Cooper ME, Van Raalte DH (2025) GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest 135(21):e194749. https:\/\/doi.org\/10.1172\/JCI194749","journal-title":"J Clin Invest"},{"issue":"9","key":"11013_CR20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS et al (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34(9):1234\u20131247e9. https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013","journal-title":"Cell Metab"},{"key":"11013_CR25","doi-asserted-by":"publisher","unstructured":"Delacre M, Lakens D, Ley C, Liu L, Leys C (2021) Why Hedges\u2019 g*s based on the non-pooled standard deviation should be reported with Welch\u2019s t-test [Internet]. PsyArXiv; [cited 2026 Aug 6]. Available from: https:\/\/osf.io\/tu6mp_v1https:\/\/doi.org\/10.31234\/osf.io\/tu6mp","DOI":"10.31234\/osf.io\/tu6mp"},{"key":"11013_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/948417","volume":"2015","author":"J Donate-Correa","year":"2015","unstructured":"Donate-Correa J, Mart\u00edn-N\u00fa\u00f1ez E, Muros-de-Fuentes M, Mora-Fern\u00e1ndez C, Navarro-Gonz\u00e1lez JF (2015) Inflammatory Cytokines in Diabetic Nephropathy. J Diabetes Res 2015:1\u20139. https:\/\/doi.org\/10.1155\/2015\/948417","journal-title":"J Diabetes Res"},{"issue":"1","key":"11013_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/0960327114531995","volume":"34","author":"H Elbe","year":"2015","unstructured":"Elbe H, Vardi N, Esrefoglu M, Ates B, Yologlu S, Taskapan C (2015) Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum Exp Toxicol 34(1):100\u2013113. https:\/\/doi.org\/10.1177\/0960327114531995","journal-title":"Hum Exp Toxicol"},{"key":"11013_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76498","author":"WN Hauwanga","year":"2024","unstructured":"Hauwanga WN, Abdalhamed TY, Ezike LA, Chukwulebe IS, Ko Oo A, Wilfred A et al (2024) The pathophysiology and vascular complications of diabetes in chronic kidney disease: a comprehensive review. Cureus. https:\/\/doi.org\/10.7759\/cureus.76498","journal-title":"Cureus"},{"issue":"6","key":"11013_CR32","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.ekir.2025.03.049","volume":"10","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Lu Z, Du Y, Duffin KL, Coskun T, Haupt A et al (2025) The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and\/or Obesity. Kidney Int Rep 10(6):1980\u20131992. https:\/\/doi.org\/10.1016\/j.ekir.2025.03.049","journal-title":"Kidney Int Rep"},{"issue":"2","key":"11013_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1214\/aoms\/1177704172","volume":"34","author":"JL Hodges","year":"1963","unstructured":"Hodges JL, Lehmann EL (1963) Estimates of Location Based on Rank Tests. Ann Math Stat 34(2):598\u2013611. https:\/\/doi.org\/10.1214\/aoms\/1177704172","journal-title":"Ann Math Stat"},{"issue":"3","key":"11013_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/jpbs.JPBS_239_19","volume":"12","author":"A Kaikini","year":"2020","unstructured":"Kaikini A, Dhodi D, Muke S, Peshattiwar V, Bagle S, Korde A et al (2020) Standardization of type 1 and type 2 diabetic nephropathy models in rats: Assessment and characterization of metabolic features and renal injury. J Pharm Bioallied Sci 12(3):295. https:\/\/doi.org\/10.4103\/jpbs.JPBS_239_19","journal-title":"J Pharm Bioallied Sci"},{"key":"11013_CR18","doi-asserted-by":"publisher","first-page":"116343","DOI":"10.1016\/j.bbr.2026.116343","volume":"514","author":"U Keskin","year":"2026","unstructured":"Keskin U, Alt\u0131n E, Kara MK, Tekin B, \u00c7ak\u0131r\u00e7oban KN, \u00d6zatik FY et al (2026) Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. Behav Brain Res 514:116343. https:\/\/doi.org\/10.1016\/j.bbr.2026.116343","journal-title":"Behav Brain Res"},{"key":"11013_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/IJNRD.S103784","volume":"9","author":"M Kitada","year":"2016","unstructured":"Kitada M, Ogura Y, Koya D (2016) Rodent models of diabetic nephropathy: their utility and limitations. Int J Nephrol Renov Dis 9:279\u2013290. https:\/\/doi.org\/10.2147\/IJNRD.S103784","journal-title":"Int J Nephrol Renov Dis"},{"key":"11013_CR11","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","volume":"63","author":"PJ Knerr","year":"2022","unstructured":"Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hj\u00f8llund KR, He Y et al (2022) Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice. Mol Metab 63:101533. https:\/\/doi.org\/10.1016\/j.molmet.2022.101533","journal-title":"Mol Metab"},{"issue":"5","key":"11013_CR12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dc20-2839","volume":"44","author":"R Krist\u00f3fi","year":"2021","unstructured":"Krist\u00f3fi R, Bodegard J, Norhammar A, Thuresson M, Nathanson D, Nystr\u00f6m T et al (2021) Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. Diabetes Care 44(5):1211\u20131218. https:\/\/doi.org\/10.2337\/dc20-2839","journal-title":"Diabetes Care"},{"key":"11013_CR13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32248","author":"M Majeed","year":"2022","unstructured":"Majeed M, Ahmed F, Teeling M (2022) The prevalence of chronic kidney disease and albuminuria in patients with type 1 and Type 2 diabetes attending a single centre. Cureus. https:\/\/doi.org\/10.7759\/cureus.32248","journal-title":"Cureus"},{"issue":"2","key":"11013_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"A Nair","year":"2016","unstructured":"Nair A, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27. https:\/\/doi.org\/10.4103\/0976-0105.177703","journal-title":"J Basic Clin Pharm"},{"key":"11013_CR17","doi-asserted-by":"publisher","unstructured":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals [Internet]. 8th ed. Washington, DC: National Academies Press (2011) [cited 2025 Sep 1]. Available from: http:\/\/www.nap.edu\/catalog\/12910https:\/\/doi.org\/10.17226\/12910","DOI":"10.17226\/12910"},{"issue":"5","key":"11013_CR30","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2337\/db15-0519","volume":"65","author":"BK Nayak","year":"2016","unstructured":"Nayak BK, Shanmugasundaram K, Friedrichs WE, Cavaglierii RC, Patel M, Barnes J et al (2016) HIF-1 Mediates Renal Fibrosis in OVE26 Type 1 Diabetic Mice. Diabetes 65(5):1387\u20131397. https:\/\/doi.org\/10.2337\/db15-0519","journal-title":"Diabetes"},{"issue":"9","key":"11013_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/08941939.2020.1716118","volume":"34","author":"H Ozlu","year":"2021","unstructured":"Ozlu H, Cakir Gundogdu A, Elmazoglu Z, Take Kaplanoglu G, Oktar L, Karasu C (2021) Bacopa Monnieri Protects the Directly Affected Organ as Well as Distant Organs Against I\/R Injury by Modulating Anti-Inflammatory and Anti-Nitrosative Pathways in A Rat Model for Infra-Renal Aortic Occlusion. J Invest Surg 34(9):935\u2013946. https:\/\/doi.org\/10.1080\/08941939.2020.1716118","journal-title":"J Invest Surg"},{"issue":"15","key":"11013_CR4","doi-asserted-by":"publisher","first-page":"8668","DOI":"10.3390\/ijms23158668","volume":"23","author":"J Rico-Fontalvo","year":"2022","unstructured":"Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Y\u00e1nez-Rodr\u00edguez T, Mart\u00ednez-\u00c1vila MC et al (2022) Molecular Mechanisms of Diabetic Kidney Disease. Int J Mol Sci 23(15):8668. https:\/\/doi.org\/10.3390\/ijms23158668","journal-title":"Int J Mol Sci"},{"issue":"10401","key":"11013_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S et al (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529\u2013544. https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X","journal-title":"Lancet"},{"issue":"5","key":"11013_CR7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K et al (2022) Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 102(5):990\u2013999. https:\/\/doi.org\/10.1016\/j.kint.2022.06.013","journal-title":"Kidney Int"},{"issue":"1","key":"11013_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.15562\/bmj.v6i1.299","volume":"6","author":"DA Sindhughosa","year":"2017","unstructured":"Sindhughosa DA, Pranamartha AGMK (2017) The involvement of proinflammatory cytokines in diabetic nephropathy: Focus on interleukin 1 (IL-1), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-\u03b1) signaling mechanism. Bali Med J 6(1):44. https:\/\/doi.org\/10.15562\/bmj.v6i1.299","journal-title":"Bali Med J"},{"issue":"1","key":"11013_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13098-025-01831-4","volume":"17","author":"A Siniukovich","year":"2025","unstructured":"Siniukovich A, Travlos CK, Freedman S, Mavrakanas TA, Gariani K (2025) Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD. Diabetol Metab Syndr 17(1):247. https:\/\/doi.org\/10.1186\/s13098-025-01831-4","journal-title":"Diabetol Metab Syndr"},{"key":"11013_CR6","doi-asserted-by":"publisher","first-page":"1459752","DOI":"10.3389\/fmed.2024.1459752","volume":"11","author":"S Song","year":"2024","unstructured":"Song S, Ni J, Sun Y, Pu Q, Zhang L, Yan Q et al (2024) Association of inflammatory cytokines with type 2 diabetes mellitus and diabetic nephropathy: a bidirectional Mendelian randomization study. Front Med 11:1459752. https:\/\/doi.org\/10.3389\/fmed.2024.1459752","journal-title":"Front Med"},{"issue":"2","key":"11013_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1037\/1082-989X.9.2.164","volume":"9","author":"JH Steiger","year":"2004","unstructured":"Steiger JH (2004) Beyond the F Test: Effect Size Confidence Intervals and Tests of Close Fit in the Analysis of Variance and Contrast Analysis. Psychol Methods 9(2):164\u2013182. https:\/\/doi.org\/10.1037\/1082-989X.9.2.164","journal-title":"Psychol Methods"},{"issue":"1","key":"11013_CR29","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1038\/s41598-025-87319-7","volume":"15","author":"RU Syed","year":"2025","unstructured":"Syed RU, Moni SS, Hussein W, Alhaidan TMS, Abumilha SMY, Alnahdi LK et al (2025) Effect of cubebin against streptozotocin-induced diabetic nephropathy rats via inhibition TNF-\u03b1\/NF-\u03baB\/TGF-\u03b2: in vivo and in silico study. Sci Rep 15(1):4369. https:\/\/doi.org\/10.1038\/s41598-025-87319-7","journal-title":"Sci Rep"},{"issue":"4","key":"11013_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TWC Tervaert","year":"2010","unstructured":"Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB et al (2010) Pathologic Classification of Diabetic Nephropathy. J Am Soc Nephrol 21(4):556\u2013563. https:\/\/doi.org\/10.1681\/ASN.2010010010","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"11013_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1440-1797.2007.00796.x","volume":"12","author":"GH Tesch","year":"2007","unstructured":"Tesch GH, Allen TJ (2007) Rodent models of streptozotocin-induced diabetic nephropathy (Methods in Renal Research). Nephrology 12(3):261\u2013266. https:\/\/doi.org\/10.1111\/j.1440-1797.2007.00796.x","journal-title":"Nephrology"},{"key":"11013_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/697010","volume":"2015","author":"S Toth-Manikowski","year":"2015","unstructured":"Toth-Manikowski S, Atta MG (2015) Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. J Diabetes Res 2015:1\u201316. https:\/\/doi.org\/10.1155\/2015\/697010","journal-title":"J Diabetes Res"},{"issue":"8","key":"11013_CR37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6(8):605\u2013617. https:\/\/doi.org\/10.1016\/S2213-8587(18)30104-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"11013_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4236\/ojneph.2023.133030","volume":"13","author":"PM Wandile","year":"2023","unstructured":"Wandile PM (2023) Diabetic Nephropathy and Management. Open J Nephrol 13(3):317\u2013327. https:\/\/doi.org\/10.4236\/ojneph.2023.133030","journal-title":"Open J Nephrol"},{"key":"11013_CR28","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.2147\/JIR.S391473","volume":"15","author":"J Wang","year":"2022","unstructured":"Wang J, Feng Y, Zhang Y, Liu J, Gong L, Zhang X et al (2022) TNF-\u03b1 and IL-1\u03b2 promote renal podocyte injury in T2DM rats by decreasing glomerular VEGF\/eNOS expression levels and altering hemodynamic parameters. J Inflamm Res 15:6657\u20136673. https:\/\/doi.org\/10.2147\/JIR.S391473","journal-title":"J Inflamm Res"},{"key":"11013_CR3","doi-asserted-by":"publisher","first-page":"586892","DOI":"10.3389\/fphar.2020.586892","volume":"11","author":"C Zoja","year":"2020","unstructured":"Zoja C, Xinaris C, Macconi D (2020) Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets. Front Pharmacol 11:586892. https:\/\/doi.org\/10.3389\/fphar.2020.586892","journal-title":"Front Pharmacol"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-11013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-026-11013-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-026-11013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:34:32Z","timestamp":1792085672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-026-11013-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11013"],"URL":"https:\/\/doi.org\/10.1007\/s10735-026-11013-9","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"value":"1567-2379","type":"print"},{"value":"1567-2387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and European Union Directive 2010\/63\/EU on the protection of animals used for scientific purposes. The original animal experiment was approved by the K\u00fctahya Health Sciences University Animal Experiments Local Ethics Committee (Decision No: 2024.01.06, Date: 30.01.2024), and the renal analyses reported in the present study were approved by the same committee under a separate decision (Decision No: 2025.06.05, Date: 29.05.2025). No additional animals were used for the present study; kidney tissues were obtained from archived material of the same cohort in accordance with the 3Rs principle of reduction.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"343"}}